Upstream process development with a kLa criterion within the Bione single-use bioreactor

  • <<
  • >>

BlueskyReddit

The FDA's Quality by Design (QbD) directive emphasizes the importance of comprehensive bioprocess characterization and understanding in future bioprocess development. It is recommended that process development incorporates a central criterion that describes the extracellular environment, aligning with this philosophy. Accordingly, we conducted innovative HEK-293 batch process development within the BIOne SUB, employing a kLa central criterion to establish operational definitions for our volume-dependent parameters.

Access Now

    Please fill out the information below to access the selected content. If you are already registered, and this information will be filled out for you.
  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • By submitting this form, you consent to Cell & Gene Therapy Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.